International
The Morning Science

What science found today

‹
 

Launch

With FDA nod, Regeneron brings an RNAi drug to autoimmune disease

BioPharma Dive · By Ben Fidler ·

The Brief

  • The FDA has approved Livsayis, Regeneron's first marketed RNAi drug, for an autoimmune disease.
  • Livsayis is the product of a collaboration between Regeneron and Alnylam.
  • It will compete with established autoimmune medicines from AstraZeneca and Argenx.

Why it matters

It is a new approved drug built on RNA interference, a gene-silencing approach, and it adds a competitor in the autoimmune treatment market.

Who’s affected

  • patients with autoimmune disease
  • researchers and clinicians working on RNA interference therapies
  • pharmaceutical industry analysts

The product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.

How do you feel about this?

0 Comments

    With FDA nod, Regeneron brings an RNAi drug to autoimmune disease – The Morning Science